After getting off to an extremely slow start, sales of Novartis AG's heart failure drug Entresto (sacubitril/valsartan) are rocketing and the Swiss major has presented more real-world data that it hopes will convince physicians and payers even more about the benefits of the therapy.
Interim findings from the CHAMP-HF registry have been unveiled at the European Society of Cardiology Heart Failure congress in Vienna,...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
